Nyxoah Secures $27 Million in At-the-Market Offering

Belgian medical technology company, Nyxoah SA, has successfully raised $27 million through its at-the-market offering. This initiative saw the company sell 3 million shares, priced according to current market value on Nasdaq, to a single U.S.-based healthcare investor. The financial transaction bolsters Nyxoah's balance sheet and enhances its focus on the U.S. market, where it plans to launch its innovative Genio® system for Obstructive Sleep Apnea (OSA).

The process was facilitated by Cantor Fitzgerald & Co., acting as the sales agent. Nyxoah's CEO, Olivier Taelman, highlighted the importance of this investment in strengthening the company's financial position and supporting its strategic U.S. market entry. The company is capitalizing on positive results from its DREAM pivotal study to advance its regulatory and commercialization efforts in the U.S.